# Gluetacs Therapeutic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gluetacs-therapeutic

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (May 31, 2024)
- Investors on record: 8

## About

Based in Shanghai, China and established in 2020, Gluetacs Therapeutic operates as a small-molecule innovative medicine company that focuses on proteolysis targeting chimeras and provides proteolysis targeting drugs (PROTAD). In November 2020, Gluetacs Therapeutic reached an exclusive license cooperation agreement for the research and development of small-molecule antitumor drugs worth more than RMB 1 billion. The co-founder as well as the CEO, Xiaobao Yang, worked at the Institute of Immunochemistry, University of Shanghai for Science and Technology. In May 2024, it closed series A funding.

Gluetacs Therapeutic focuses on the development of novel oral small-molecule drugs by using protein degradation technology, and has established its own intellectual property rights for the development of molecular gel degraders (GLUE) and dual mechanism degraders (GLUETAC). The company has also established an artificial intelligence virtual screening platform, an in vitro pharmacodynamic screening platform, a pharmacokinetic platform, a proteomics platform and a tumor animal pharmacodynamic modeling platform. Its products are used in the fields of oncology and autoimmune diseases.

Gluetacs Therapeutic generates revenue by licensing its proprietary drug candidates, providing drug development services, and collaborating with pharmaceutical companies on research and development projects.

The company will use the series A funding for the clinical Phase I advancement of the product pipelines GT919 and GT929 and the development of preclinical programs.

## Funding rounds

- Series A, May 31, 2024 — Leading Capital, Gortune Investment, Huangpu Pharmaceutical Fund, Sinan Yuanke
- Angel, Mar 23, 2021 — Grains Valley Venture Capital, Dynamic Capital, CSPC NBP Pharmaceutical, Shenghui Jingchen Investment

## Investors

- Grains Valley Venture Capital (https://capitalatlas.ai/funds/grains-valley-venture-capital) — Angel
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Angel
- CSPC NBP Pharmaceutical — Angel
- Shenghui Jingchen Investment (https://capitalatlas.ai/funds/shenghui-jingchen-investment) — Angel
- Leading Capital — Series A
- Gortune Investment (https://capitalatlas.ai/funds/gortune-investment) — Series A
- Huangpu Pharmaceutical Fund — Series A
- Sinan Yuanke (https://capitalatlas.ai/funds/sinan-yuanke) — Series A